Renal membrane-bound CA activity facilitates urinary acidification (16, 45) and may be rate limiting for acid-base transport (23) . In the lung, however, only 5-8% of the total CO 2 excretion in vivo is attributable to membrane-bound CA activity, whereas 60-70% is attributable to red blood cell CA II (3, 38) . Although membrane-bound CA activity in normal epithelia has been classically attributed to CA IV, the relative contribution to acid-base transport of CA IV, XII, and XIV remains to be determined in specific tissues, including various nephron segments.
Chronic acidosis induced by ammonium chloride (NH 4 Cl) loading upregulates renal SDS-resistant hydratase activity both in rabbits and in mice (4) (5) (6) and CA IV mRNA expression in rabbits (42, 46) . Nevertheless, in mice with the CA II deficiency (CAD) mutation (car-2 n ) (20) , chronic acidosis is not associated with any change in CA IV immunoreactivity on Western blot analysis and immunocytochemistry (4, 5) . Discrepancy between regulation of SDS-resistant hydratase activity and that of CA IV immunoreactivity in the mouse may have resulted from lack of specificity of SDS resistance (corresponding to both CA IV and CA XIV) (25) , from low specific activity of rodent CA IV and its incomplete inactivation by SDS (40) , and possibly from several other mechanisms (4) .
Expression of membrane-bound CA in the placenta was initially suggested by inhibition of the uptake of [ 14 C]bicarbonate-CO 2 in guinea pig placenta after exposure of the fetal side (more than the maternal side) to the membrane-impermeant CA inhibitor aminothiazole (15) . Membrane-bound CA activity was shown by histochemical studies of the placenta, although considerable variability was observed among species (32) . Expression of CA IV in rat placenta was demonstrated by Fleming et al. (11) using Northern blot analysis.
We hypothesized that CA IV would be expressed in the zone of fetomaternal blood exchange, i.e., the labyrinth, and upregulated with acidosis. To assess the cellular localization and the regulation of CA IV expression, we selected mouse placenta. The latter, similar to human placenta, is hemochorial and discoid; nevertheless, mouse placenta has three trophoblast layers (hemotrichorial), whereas human placenta has only one (hemomonochorial) (27, 47) .
METHODS
Animals. B6AF1/J mice were purchased from Jackson Laboratories (Bar Harbor, ME) and studied at an age of 3-5 mo. All mice had free access to fluid and food. Animals were mated overnight once; gestational age was confirmed by fetal maturity using established criteria (41) .
We acid-loaded several mice by using a 3-to 6-day course of NH 4 Cl by daily orogastric feeding of 25 mmol/kg of NH 4 Cl (using a 5.6 mol/l solution) and by replacing drinking water with a solution of 280 mmol/l NH 4 Cl. This method of acid loading was needed to consistently induce severe metabolic acidosis, because simple replacement of the drinking water with NH 4 Cl minimally decreased average pH (7.28 Ϯ 0.05, mean Ϯ SD) and yielded metabolic acidosis in only one-third of the animals.
Animals were killed by intraperitoneal administration of 100 mg/kg pentobarbital sodium. Control animals were killed at either 11, 15, or 19 days of pregnancy. Acid-loaded animals were killed at 19 days of pregnancy, after 3-4 days of acid loading for Northern blot analysis and 3-4 days or 5-6 days for Western blot analysis. Some animals were used for blood gas analysis and Northern blot analysis. Other animals were used for Western blot analysis, and the last group was used for immunocytochemistry. All placentas from the same pregnant mouse were pooled as an n of one. For each procedure, samples for the same set of animals (controls vs. acid loaded, or at various gestational ages) were run in parallel. These protocols have been approved by the Animal Institute of the Albert Einstein College of Medicine, which is an American Association for Accreditation of Laboratory Animal Careaccredited facility.
Mouse CA IV cDNA. First strand cDNA was synthesized by incubating 20-30 g of total mouse kidney RNA with 200 U of Superscript II, oligo(dT) [(dT) 18 ], deoxy-nucleotides, and dithiothreitol at 45°C for 1 h, and then treating with RNAse H. PCR was done with 1 mmol/l magnesium at an annealing temperature of 57°C; the template for nested PCR was obtained by eluting and purifying DNA of the expected size from a slice of gel after electrophoresis of the first corresponding PCR reaction. The sequences of primers, selected from Fleming's sequence (11) with the McVector program (Oxford Molecular, Oxford, UK) were as follows: R4F1, 5Ј-GCC CCC TCT ACT GAA GAT TCA CAC (sense, bp 125-146); R4F3, 5Ј-TGA GAT TCA AGC CAA GGA GCC C (sense, bp 93-116); R4B11, 5Ј-CAG CTC TCA CTC ACT GTG GAG TTT G (antisense, bp 652-628).
The 520-bp product was cloned and then sequenced using the Taq DyeDeoxy Terminator Cycle Sequencing Kit on an Applied Biosystems model 373 DNA Sequencing System (Perkin Elmer, Norwalk, CT). The sequence, 70% identical to Fleming's rat CA IV cDNA, was used to design nested primers for rapid amplification of the cDNA ends (RACE). Firststrand cDNA for 3Ј-RACE was obtained at 42°C by using Superscript II and the 3Ј-adapter primer (GIBCO BRL, Rockville, MD). First strand cDNA for 5Ј-RACE was obtained at 42°C by using Superscript II and the following antisense primer: MR5Ј9, 5Ј-CTC CTT GCT AGA TGT C.
The cDNA designed for the 5Ј-RACE was then purified and tailed with oligo(dT) at the 5Ј-end. We then did nested PCRs (3Ј-RACE and 5Ј-RACE) using a nonspecific primer provided in the corresponding kit (GIBCO BRL) and one of the following nested primers designed from the original 520-bp product: 3Ј-RACE: M4RF7, 5Ј-ACA AAG GTG AAC CCC AGA CTG AC; MR4F11, 5Ј-AGA CTG ACA CCC TTC ATC CTC GTC; 5Ј-RACE: M4RB6, 5Ј-TGT CTC CCA TCA ATA CTG TGC TCT G; MR4B4, 5Ј-CAA TAC TGT GCT CTG AAC CGT TGT C.
Nested 3Ј-RACE yielded a 1-kb product, whereas nested 5Ј-RACE yielded a 450-bp product (excluding the amplifier primer). These two products were combined by PCR using the universal amplifier primer (GIBCO BRL), yielding a final 1.2-kb product, which was cloned using the pAmp10 vector and DH5␣ competent cells. The consensus sequence from four separate CA IV cDNA clones (LPB) was 99% identical to the published full-length mouse CA IV cDNA obtained by library screening by Tamai et al. (39) , except on the 5Ј-end.
Northern blot analysis. Placentae were frozen in liquid nitrogen and kept at Ϫ70°C until thawing. They were mechanically homogenized using a Teflon homogenizer. Total RNA was extracted using the single-step acid guanidium thiocyanate-phenolchloroform method (8, 9) . Quality of the RNA was confirmed by a ratio of optical density at 280 nm (OD 280)/OD 260 Ն 1.5 and by visualization of the 28S and 18S bands on a minigel electrophoresis using ethidium bromide staining and ultraviolet transillumination. Electrophoresis of 15 g of total RNA was done in 4 h using a formaldehyde gel with 1ϫ borate buffer. RNA was transferred overnight to a Hybond N membrane (Amersham Life Sciences, Arlington Heights, IL) and fixed to the membrane by ultraviolet cross-linking. The membrane was prehybridized in a rotatory oven for 1-3 h at 42°in 50% formamide, 5ϫ sodium citrate-sodium chloride (SSC), 50 mmol/l sodium phosphate pH 6.8, 5% Denhardt solution, 2.5% denatured salmon sperm DNA, 0.1% SDS, and 10 mmol/l EDTA in DEPC H 2 O. The RNA was hybridized overnight at 42°with a cDNA probe that had been obtained by labeling the purified full-length CA IV cDNA with 32 P using the New Megaprime kit (Amersham) (1.5 ϫ 10 6 cpm per membrane). The membrane was washed successively at 55°C with 2ϫ SSC-0.5% SDS, at 55°with 1ϫ SSC/0.2% SDS and at 65°with 1ϫ SSC-0.1% SDS; based on background radioactivity detected using a Geiger counter, some blots were then washed at 65°C using 0.3ϫ SSC with 0.1% SDS. The membrane was then exposed to a radiosensitive film (Biomax MS, Eastman Kodak, Rochester, NY) and incubated at Ϫ70°C for 6-18 h. The membrane was then stripped and reprobed with a glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA probe prepared as described above, using a cDNA purchased from Ambion (Austin, TX).
After scanning the film using an HP Scanner IICX, we measured the density of the bands using two-dimension analysis with the Zero-Dscan Image Analysis System (Scanalytics, Billerica, MA) and corrected the value for adjacent background. The abundance of CA IV mRNA in each sample was normalized by calculating the ratio of the density of the CA IV band to that of the GAPDH band. To compare CA IV expression among samples run in different Northern blots, we normalized the ratio by running a sample from the same animal in all gels.
Western blot analysis. We used the same technique as described previously (4) . Briefly, 5-10 l of solubilized microsomal membranes were run on reducing SDS-PAGE and transferred overnight into nitrocellulose membranes. The amount and dilution of the sample were calculated to yield 30 g of protein for microsomal membranes. Blocking and antisera incubations were all done in PBS with 3% albumin and 0.1% Tween 20. After blocking for 1 h, the membrane was incubated for 2 h with a 1:2,500 dilution of rabbit antiserum to mouse CA IV or to recombinant human CA IV (gifts from W. S. Sly). These antisera have been shown to be specific and sensitive to CA IV; the first antiserum recognizes two bands in mouse lung and kidney microsomal membranes (39 and 63 kDa), whereas the latter recognizes only the 39-kDa band (4) . In one sample we used as negative control a random preimmune rabbit serum. The membrane was then incubated for 1 h with a 1:5,000 dilution of goat anti-rabbit IgG-antiserum conjugated to peroxidase. Bands were visualized using enhanced chemiluminescence (ECL; Amersham or Renaissance, NEN Life Science Products, Boston, MA). Chemiluminescence-sensitive film (Hyperfilm ECL, Amersham) was exposed to the membrane for 3-20 s. Densitometry is described above.
Immunocytochemistry. After anesthesia, the animals were perfused with a 25-gauge butterfly inserted into the left ventricle and connected to a peristaltic pump (Cole Parmer, Chicago, IL). We first infused ice-cold PBS (i.e., 10 mM sodium phosphate, 138 mM NaCl at pH 7.4) for 30 s, then 0.5% paraformaldehyde in PBS for 2 min, and then 18% sucrose in PBS for 2 min. The placenta was incubated in sucrose until sinking to preserve cell compartments (7). The tissue was then surrounded with embedding medium (OCT Compound, Sakura Finetech USA, Torrance, CA), snap-frozen in 2-methylbutane placed on dry ice, and kept at Ϫ70°C. Six-to ten-micrometer cryostat sections were prepared using L-lysin-coated slides, let to dry at room temperature, and kept at Ϫ70°C. Slides were stained using the Vectastain peroxidase ABC kit and the DAB substrate kit (yielding a brown color) (Vector Laboratories, Burlingame, CA). We used three modifications suggested by the manufacturer: incubating the ABC reagents in 0.5 M sodium chloride to reduce ionic interactions, incubating the primary and the secondary antisera in normal rabbit serum to reduce false-positive reactions, and incubating the slides in 0.3% H 2 O 2 in 40% methanol in PBS overnight to block endogenous peroxidase activity. A coverslip was mounted in Mowiol (Calbiochem, La Jolla, CA), which was allowed to dry overnight at 4°C. Negative controls for immunocytochemistry were identical tissues simultaneously submitted to the exact same procedures, except that incubation with the primary antiserum was replaced by incubation with nonimmune rabbit serum. Tissues were counterstained with hematoxylin (Vector Laboratories).
Tissues were visualized with a Nikon Diaphot-inverted microscope equipped with a 75-W Xenon bulb, a ϫ4 or a ϫ50 water immersion lens, and a Nikon N70 35 mm camera with 400 ASA slide film. We used established nomenclature for the anatomy of mouse placenta (24, 31, 41, 47) .
Statistical analysis and sample size. We compared continuous variables by unpaired Student t-test or by ANOVA followed if significant by Dunnet's C test or Tukey's test, as appropriate. A P Ͻ 0.05 was considered statistically significant. Values are expressed as means Ϯ SD. For each experiment, sample size was calculated (using preliminary data) to reach a power of 0.8 of detecting an effect size of 2.
RESULTS

Description of the animals and physiological data.
Acid-loaded animals received a mean of 66 Ϯ 18 mmol ⅐ kg Ϫ1 ⅐ day Ϫ1 of NH 4 Cl. They had a significantly lower blood pH than control animals (7.06 Ϯ 0.04, n ϭ 4 vs. 7.36 Ϯ 0.04, n ϭ 11, P Ͻ 0.001) and a lower plasma bicarbonate concentration (11.0 Ϯ 1.2 mmol/l, n ϭ 4, vs. 21.3 Ϯ 1.9 mmol/l, n ϭ 11, P Ͻ 0.001). Values in controls were similar to those reported previously in nonpregnant adult mice (4).
Northern blot analysis. CA IV mRNA was detected as a single 1.2-kb band, as reported previously (39) . Northern blot analysis showed a significant increase in the ratio of the density of CA IV mRNA to that of GAPDH from day 11 (1.00 Ϯ 0.62 arbitrary units, n ϭ 7) to day 15 (3.30 Ϯ 0.63, n ϭ 7) and day 19 (3.28 Ϯ 0.76, n ϭ 8) (P Ͻ 0.001 day 11 vs. day 15 and day 11 vs. day 19; Fig. 1A) .
The ratio of the density of CA IV mRNA to that of GAPDH did not significantly change with a 3-to 4-day maternal acid loading (1.00 Ϯ 0.12 arbitrary units in 9 controls vs. 1.22 Ϯ 0.44 in 12 acid-loaded animals, P ϭ 0.12; Fig. 1B) .
Western blot analysis. The antiserum to mouse CA IV recognized one major band migrating at 39 kDa and one minor band at 63 kDa, which was visible only in some membranes (Fig. 2A) ; these were the same molecular weights as those reported previously for CA IV in mouse kidney (4) . The antiserum to human CA IV recognized only the 39-kDa band (data not shown). Expression of the 39-kDa band in the whole placenta increased significantly from day 11 (1. Fig. 2B ).
The expression of CA IV (39-kDa band) on day 19 did not change significantly with 3-4 days of maternal acidosis (1.00 Ϯ 0.33 units, n ϭ 6 in controls vs. 1.15 Ϯ 0.24 units, n ϭ 7, in acid-loaded animals; Fig. 2A ). In preliminary experiments (power 0.65), we observed a reduction of CA IV after a 5-to 6-day acid loading (1.00 Ϯ 0.12 units, n ϭ 4 controls, vs. 0.51 Ϯ 0.33, n ϭ 4 acid-loaded animals, P ϭ 0.032).
Immunocytochemistry. CA IV immunoreactivity was found in the labyrinth, the endodermal layer of the yolk sac, the decidua, and the uterine epithelium, but not in the junctional zone (trophosphongium) and the zone of giant cells (Fig. 3) . CA IV was expressed over the entire area of the labyrinth, which extended from the periumbilical area toward the periphery of the placenta from 11 to 19 days (Figs. 3 and 4) . During gestation the proportion of the placenta occupied by the labyrinth increased both laterally and transversally. The rate of growth of the labyrinth was quantified using the labyrinth-to-placenta thickness ratio at the center of the placenta. The thickness ratio increased from 0.38 Ϯ 0.14 (n ϭ 5) at 11 days to 0.57 Ϯ 0.07 (n ϭ 5) at 15 days and 0.70 Ϯ 0.12 (n ϭ 5) at term (ANOVA, P ϭ 0.003; day 11 vs. day 15, P ϭ 0.046, day 11 vs. day 19, P ϭ 0.002).
Perfusion-fixation removed most maternal red blood cells but fixed fetal red blood cells in situ, thereby facilitating the differentiation of fetal blood vessels from maternal spaces (Fig. 5) .
In the labyrinth (Fig. 5) , heavy CA IV staining was observed in the trophoblast, with, in some places, intense staining on the apical membrane of the superficial layer, i.e., in contact with maternal spaces. Giant cells did not express CA IV. Weak staining for CA IV was observed in many fetal endothelial cells at 11 days (Fig. 5A) but not later in gestation (Fig. 5, C and E) .
In the intraplacental yolk sac (Fig. 6) , CA IV was expressed in the visceral or endodermal layer, i.e., the columnar layer adjacent to large umbilical vessels (24) . There was no CA IV expression in the parietal layer resting on Reichert's membrane; however, CA IV was expressed on all trophoblastic cells resting on the other side of Reichert's membrane. There was no CA IV expression in the periplacental parietal layer of the yolk sac (periplacental omphalopleure).
In the endodermal layer of the extraplacental yolk sac (Fig.7) , CA IV was expressed in the outermost cells of the villi, mainly at the upper half of the cells.
Strong CA IV expression was also observed in the uterine epithelium (juxtauterine bilaminar omphalopleure), which is adjacent to the Reichert membrane before its disappearance at the end of gestation (Fig. 8 ).
DISCUSSION
Our data showed strong CA IV immunoreactivity in mouse labyrinthine trophoblast and in the endodermal layer of the yolk sac (both intra-and extraplacental) and weak CA IV staining in fetal endothelial cells at 11 days. The area of strong expression of CA IV in mouse placenta increased with gestation, along with the increase in size of the labyrinthine area (41) . In rat placenta the trophoblast accounts for 30% of the placenta by weight at 12 days of pregnancy and 60% at 20 days (10). In the mouse, most of the increase in size of the labyrinth occurs between day 11 and day 15, with less increment from day 15 to day 19. The thickness ratio (labyrinth-to-total placenta) at 11 days and 15 days was, respectively, 54 and 81% of term values. In addition, branching of major umbilical vessels and development of the intraplacental yolk sac occurs from day 10 to day 14, followed by further capillary development.
The abundance of CA IV mRNA and CA IV immunoreactive expression, measured, respectively, by Northern and Western blot analysis, tripled from day 11 to day 15, in parallel with the rapid labyrinthine growth. From day 15 to day 19, the abundance of CA IV mRNA remained stable, whereas that of CA IV immunoreactive protein decreased and labyrinthine growth slowed down. This discrepancy between CA IV mRNA, CA IV immunoreactive protein, and labyrinthine growth at the end of gestation could have occurred in part from fetal capillary growth into the trophoblast and possibly from changes in the rate of CA IV protein synthesis or catabolism.
Previous immunochemical studies have shown evidence for expression of CA II but not CA I and CA III in bovine placenta (28) . Human placenta expresses CA I and II (1, 2, 26) in the syncytiotrophoblast and, especially CA II, in fetal villous endothelium of mature placenta (26) . Ridderstråle and coauthors (32) showed considerable species heterogeneity of CA expression in placenta. Histochemistry of human placenta showed Fig. 3 . CA IV immunocytochemistry. Chorionic plate and labyrinth, low magnification (ϫ40). A and B: 11 days; C and D, 15 days; E and F, 19 days; A, C, E, CA IV; B, D, F, negative controls; labyrinth, long arrow; endodermal layer of the extraplacental yolk sac, short black arrow; endodermal layer of the intraplacental yolk sac, small arrowhead; junctional zone and zone of giant cells, triangle. CA IV appears as brown pigmentation, which is not visible in negative controls. Most CA IV immunoreactivity is found in the labyrinth (long arrow). Note a progressive increase in the area of expression of CA IV with gestational age, corresponding to the increase in size of the labyrinth. CA IV is also expressed on the endodermal layers of the extraplacental yolk sac (short black arrow) and of the intraplacental yolk sac (arrowhead).
CA activity only in fetal capillaries but not in the trophoblast (32) . In contrast, histochemistry of rat placenta showed CA activity in the trophoblast but not in fetal capillaries (19, 32) . Thus our results using CA IV immunocytochemistry in mature mouse placenta match Ridderstråle's histochemical data in rat placenta.
In addition, our data show evidence for CA IV immunoreactive expression in the endodermal layers of the intrauterine and extrauterine yolk sac and in the uterine epithelium adjacent to Reichert's membrane. The role of CA IV expression at these locations remains to be determined; we hypothesize CA IV might have a role in epithelial transport. The endodermal layer of the yolk sac, whether intraplacental or extraplacental, expresses calbindin, a vitamin D-dependent calciumbinding protein implicated in calcium transfer (31) . The endodermal layer of the extraplacental yolk sac selectively transfers proteins and is the major route of transport of intact maternal immunoglobulins toward fetus in rodents (47) .
Fetal metabolism produces CO 2 , which is transferred across the placenta as dissolved CO 2 rather than bicarbonate (17, 22) . Under normal conditions, the rate of CO 2 transfer depends on the fetomaternal PCO 2 gradient, fetal and maternal blood flow rates, and the hemoglobin concentration and buffering capacity, but not on the placental membrane diffusion capacity or on usual levels of CA in fetal red blood cells (17) . The differential role of maternal and fetal CA in acid-base regulation of the fetus has been studied in human pregnancies. Maternal administration of acetazolamide does not affect fetal blood pH or PCO 2 , regardless of whether controls are studied under baseline conditions or after NH 4 Cl administration (37) . In contrast, injection of acetazolamide into lamb or human umbilical vein causes fetal acidosis and hypercapnia (22, 36) but does not decrease the fetal arteriovenous umbilical PCO 2 gradient (22); fetal acidosis and hypercapnia could be due not only to inactivation of red blood cell CA but also to inactivation of CA localized on the fetal side of the placenta. The latter could decrease conversion of bicarbonate into CO 2 and diffusion of CO 2 across the placenta (15).
We did not observe any upregulation of CA IV mRNA or immunoreactive protein in response to a 3-day maternal acid loading. After 5-6 days, CA IV immunoreactive protein decreased to half the control value, possibly due to increased protein catabolism or decreased protein synthesis during severe acidosis. Previous data in our laboratory have shown lack of upregulation of CA IV immunoreactive protein in mouse kidney and central nervous system in the presence of chronic acidosis due to congenital CAD (5, 6) . In contrast, in the rabbit, renal expression of CA IV (42) and CA II (34) mRNAs is upregulated by in vivo acidosis with a peak at 3 days, and CA II immunoreactive protein expression doubles in rat inner medullary collecting duct cells after a 2-day acidosis in vitro (33) . In the present study, we did not assess possible changes in SDS-resistant hydratase activity in the placenta because of lack of sensitivity and specificity of that method (25, 40) . It is possible that the upregulation of SDS-resistant hydratase activity we had previously observed with acidosis in rabbit and mouse kidney and in mouse central nervous system (4-6) might have in part resulted from CA IV is expressed in the trophoblast. In some cells, CA IV is mostly expressed at the apical surface, i.e., in direct contact with maternal spaces. Weak staining for CA IV is observed in fetal endothelium (long arrow) at 11 days but not later in pregnancy. Giant cells do not stain for CA IV. Note the progressive maturation of fetal red cell line (short arrow) with predominance of nucleated cells at 11 days and of mature erythrocytes at 19 days. Residual maternal erythrocytes (arrowhead) are smaller than fetal erythrocytes. Note progressive proliferation of fetal capillaries by the end of pregnancy. Fig. 6 . CA IV immunocytochemistry, chorionic plate. High magnification (ϫ500). A and B, 11 days; C and D, 15 days; E and F, 19 days; A, C, E, CA IV; B, D, F, negative controls; fetal endothelium, long arrow; fetal red cell line, short black arrow; endodermal layer of the extraplacental yolk sac, long arrowhead; endodermal layer of the intraplacental yolk sac, short open arrow; space of Duval, curved arrow; parietal layer of the intraplacental yolk sac, small arrowhead; Reichert membrane, triangle; maternal red blood cells, double-headed arrow. Endothelial cells stain for CA IV at 11 days but not later in pregnancy. CA IV is strongly expressed in the endodermal layer of the extraplacental yolk sac. There is also strong CA IV staining of the columnar epithelium surrounding the large umbilical vessels; at 15 and 19 days this epithelium is the visceral or endodermal layer of the intraplacental yolk sac. The space of Duval, situated between the endodermal layer and the parietal layer, does not contain any erythrocyte. CA IV is not expressed in the squamous epithelium or parietal layer of the intraplacental yolk sac, resting on the Reichert membrane; on the other side of the Reichert membrane is the maternal space.
CA XIV, which are smaller proteins). Indeed, the antiserum to recombinant human CA IV (provided by W. S. Sly), recognized the 39-kDa band but not the 63-kDa band, in both the kidney (4) and the placenta.
In summary, in mouse placenta, CA IV is mostly expressed in the labyrinth, at the interface between fetal capillaries and maternal blood. The expression of CA IV mRNA and that of CA IV immunoreactive protein in mouse placenta peak during the second third of gestation. Maternal acidosis during the last quarter of pregnancy does not upregulate CA IV mRNA or immunoreactive protein in mouse placenta.
Perspectives
Immunocytochemistry showed strong CA IV expression in mouse placenta in the labyrinth, where it is expected to facilitate acid-base transfer between maternal and fetal blood. Maternal acidosis did not upregulate the expression of CA IV mRNA or immunoreactive protein.
In addition, we found CA IV expression in the endodermal layer of the yolk sac. Further experiments are required to determine whether CA IV expression in this location may play a role in facilitating transport across this specialized layer. 
